Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 59,742	$ 16,952
Available-for-sale investments	56,612	14,737
Other receivables	129	2,039
Prepaid expenses	5,089	1,803
Total current assets	121,572	35,531
Property and equipment, net	707	899
Right-of-use assets	1,479	2,083
Other assets	158	213
Total assets	123,916	38,726
Current liabilities:
Accounts payable	900	1,431
Accrued expenses	3,971	3,572
Current portion of operating lease liability	949	861
Total current liabilities	5,820	5,864
Long-term operating lease liability, net of current portion	657	1,378
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares; Class X Convertible Preferred Stock issued and outstanding shares – 0 as of September 30, 2021 (unaudited) and December 31, 2020, respectively
Common stock, $0.001 par value per share; 42,500,000 and 21,425,000 authorized shares as of September 30, 2021 and December 31, 2020, respectively; issued and outstanding shares – 27,790,677 (unaudited) and 11,018,954 as of September 30, 2021 and December 31, 2020, respectively	28	11
Additional paid-in capital	481,390	370,210
Accumulated other comprehensive loss	(69)	(43)
Accumulated deficit	(363,737)	(338,528)
Total aTyr Pharma stockholders’ equity	117,612	31,650
Noncontrolling interest in Pangu BioPharma Limited	(173)	(166)
Total stockholders' equity	117,439	31,484
Total liabilities and stockholders’ equity	$ 123,916	$ 38,726